Jeff Yass’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.1M Buy
104,400
+16,600
+19% +$641K ﹤0.01% 4809
2026
Q2
$3.2M Buy
87,800
+29,800
+51% +$940K ﹤0.01% 5500
2026
Q1
$1.62M Sell
58,000
-5,400
-9% -$177K ﹤0.01% 6658
2025
Q4
$2.37M Sell
63,400
-84,800
-57% -$2.79M ﹤0.01% 5287
2025
Q3
$4.08M Buy
148,200
+85,100
+135% +$2.93M ﹤0.01% 4433
2025
Q2
$1.99M Buy
63,100
+34,400
+120% +$1.11M ﹤0.01% 5785
2025
Q1
$953K Sell
28,700
-400
-1% -$14.3K ﹤0.01% 7379
2024
Q4
$1M Sell
29,100
-2,300
-7% -$79K ﹤0.01% 6931
2024
Q3
$1.26M Sell
31,400
-8,400
-21% -$295K ﹤0.01% 6292
2024
Q2
$1.2M Buy
39,800
+13,000
+49% +$391K ﹤0.01% 6145
2024
Q1
$900K Buy
26,800
+10,600
+65% +$340K ﹤0.01% 7157
2023
Q4
$523K Sell
16,200
-47,100
-74% -$1.31M ﹤0.01% 8557
2023
Q3
$2.07M Buy
63,300
+27,400
+76% +$951K ﹤0.01% 5047
2023
Q2
$1.26M Buy
35,900
+15,600
+77% +$539K ﹤0.01% 6156
2023
Q1
$663K Buy
+20,300
New +$924K ﹤0.01% 7866
2022
Q4
– Sell
-8,900
Closed -$394K – 12943
2022
Q3
$394K Buy
8,900
+3,000
+51% +$146K ﹤0.01% 9090
2022
Q2
$288K Buy
5,900
+1,300
+28% +$58.5K ﹤0.01% 9668
2022
Q1
$224K Buy
+4,600
New +$188K ﹤0.01% 10963

Other funds holding HRMY

Jeff Yass's HRMY Position: Q3 2026 in Review

Jeff Yass reduced its Harmony Biosciences (HRMY) stake by 84% in Q3 2026, selling an estimated $4.8M and leaving 23,026 shares worth $904K. The position accounts for ﹤0.01% of the portfolio, ranked #8208.

Jeff Yass first reported a position in HRMY in Q1 2021 and has held it in 18 quarters since. The position peaked at $5.36M in Q2 2026. 358 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • Jeff Yass held 23,026 shares of Harmony Biosciences worth $904K as of Q3 2026.
  • Jeff Yass sold 124,150 Harmony Biosciences shares in Q3 2026, an estimated $4.8M.
  • Harmony Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #8208 holding.
  • Jeff Yass first reported a position in Harmony Biosciences in Q1 2021 and has held it in 18 quarters since.
  • Jeff Yass's Harmony Biosciences position peaked at $5.36M in Q2 2026.
  • 358 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.